Structure-based design of aliskiren, a novel orally effective renin inhibitor - Wikidata - wikimedia - TriplyDB

Structure-based design of aliskiren, a novel orally effective renin inhibitor

Structure-based design of aliskiren, a novel orally effective renin inhibitor

http://www.wikidata.org/entity/Q28202603

about

sameAs

Can Aliskiren be Considered as a New Novel Drug for Hypertension?Potential of RAS inhibition to improve metabolic bone disorders Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group The Catalytic Mechanism of an Aspartic Proteinase Explored with Neutron and X-ray Diffraction Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production Aliskiren: the first renin inhibitor for clinical treatment High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes Metal Ion Modeling Using Classical Mechanics Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.Purification and characterization of recombinant human renin for X-ray crystallization studies.Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.Aliskiren displays long-lasting interactions with human renin.Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis.Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis Renin and cardiovascular disease: Worn-out path, or new direction.Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.Aliskiren: An orally active renin inhibitor.Role of aliskiren in blood pressure control and renoprotection Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects Aliskiren in hypertension: evidence for its potential therapeutic value Chronic Activation of the Renin-Angiotensin System Induces Lung Fibrosis.Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva.Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice.Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers.Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug.Aliskiren, the future of renin-angiotensin system blockade?Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives.Chemistry and biology of multicomponent reactions.

P2860

Q26775106-FF98289B-6CA6-4EB2-88E2-E3C9A333624C Q26866515-85B6AE55-8D98-4C3F-981C-075C157F6C63 Q27023787-C2D6671F-8CD5-49D9-90D9-39FC3A801E9B Q27314658-5FF239E8-E9AD-4940-9718-2D65F49AE2FF Q27644661-07C643BB-A330-4854-8A61-F7E7E0711148 Q27650602-782DAC1B-586D-4165-8FBA-42580001C448 Q28269927-AFF1445E-40BC-4A08-B44C-481E94BF9503 Q28272666-20D37BB2-E901-4DAD-8780-CE7DC7B324FA Q28582700-8024F4C0-3DB1-4DDE-97B0-A01C14E1C444 Q30363020-E059E7AB-792B-4C73-BC11-7C6BD23D1CAE Q30367220-7DEF8C9D-74F4-45A7-9DE2-430E26DB4760 Q30422214-02658AA9-F710-4126-8FDF-A2021B3DECED Q33346977-9CF98C19-E90D-45D3-B541-AE1472D9D9E0 Q33403707-D10B558F-A74A-4785-85F1-2D37393FB9A0 Q33840829-5702B2C5-F646-413A-8B7C-A442AA0D9E52 Q34032089-23158880-A444-46AC-BB0D-61BA16A8F713 Q34109516-17187011-85A9-4389-88E9-40A4D5669347 Q34156850-8F19494D-D903-44AF-AE6A-7B098954E1A1 Q34175087-B18A559B-EDD2-45B1-B36F-67846A889771 Q34247173-DD2BC6F9-92B8-4618-9F14-755F80445935 Q34478776-209EF041-48D1-497E-A370-DA244BA018A8 Q34672049-C2029558-C1E9-4DD8-A45A-D8E523E23E46 Q34801804-4B28B718-D8AD-4871-8135-6E8D694BE529 Q34976482-1748E9E0-AE55-43F8-A2ED-B3283202998C Q35013037-123912C3-FA28-46C5-9F8A-779D27A5B20B Q35026735-056140BD-27CB-4BEA-96B8-08D3446F2331 Q35035662-5EB17E20-6845-490B-ADE8-B6B9D1B20393 Q35826397-A06E7F6E-BDFF-4A55-ABB0-01BB486660A6 Q35827907-F6A745F5-BF0C-450D-9D47-6DCC71BDF863 Q35876368-DB1AC435-09F3-4AE6-A9CF-17A7A2626AD0 Q36192502-94BD6487-38EB-4F73-A5F7-942D03214750 Q36451684-70E9AA5A-B4D6-41DF-939B-356F2BD9C49C Q36458652-CA2CD4A6-B096-4AE0-B999-A035755C1568 Q36565036-AFD30CD2-B082-4318-8585-5F278AB38B04 Q36675396-A819326A-FDB2-4F95-B944-0E9616F97F50 Q36688756-3AC1CF15-E1C6-4B7E-927E-8E67E775F541 Q36941829-AF20E369-3D87-4E35-B758-2B8D1ED4D6FB Q36975796-40D08D2E-29AB-46F9-A64E-052FF0571905 Q36979342-41AE7766-259D-4189-8B9D-3AA3738A1DA1 Q37017587-DF80D646-E56E-43D1-9018-5FAFC5B76D78

P2860

Structure-based design of aliskiren, a novel orally effective renin inhibitor

http://www.wikidata.org/entity/Q28202603

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@ast

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@en

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@nl

type

label

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@ast

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@en

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@nl

prefLabel

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@ast

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@en

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@nl

P1433

Q28202603-3F10FB34-18A5-462F-97EF-AAC46C277432

P1476

Q28202603-464DD607-C099-4122-ADD3-E5A4CE959219

P2093

Q28202603-0301E689-0EE9-4905-8E94-BC6F629E86BB

Q28202603-07011D9D-4A1E-415D-B3F8-A1662D9FC9D0

Q28202603-170DA997-51A1-4E47-80B7-C60268EA0232

Q28202603-1A1F3C86-010F-4820-BD52-A1D5A964F193

Q28202603-2D0A2656-CF09-4712-8E42-2FDFD50BB550

Q28202603-57D1B497-D085-4229-A33F-C1B6CD321E05

Q28202603-5902B10C-2B13-41F2-BE87-D03CD8E97755

Q28202603-59C2499B-AE50-46E3-9F77-24AE917854D6

Q28202603-5A957CAD-BEAD-41B8-B225-9AA63FF35AA2

Q28202603-5E5C9218-EA6D-4590-BE06-50C6D6E6F359

P304

Q28202603-32889941-BDD1-497C-81DD-A89683128087

P31

Q28202603-27777845-4C25-41FB-AF95-252BC2CCFDEF

P3181

Q28202603-5FADFB80-1399-40ED-9D46-342204CEA169

P356

Q28202603-F53F4FAF-348B-4090-884A-67DD29DDEACD

P407

Q28202603-9AFE3F36-FD40-466F-A32D-0DA15F28B08D

P433

Q28202603-7A4D3C93-C13F-41E0-B383-544BE0CE005F

P478

Q28202603-5CE7E485-AD7E-419F-BF5A-55360FE763FC

P50

Q28202603-4E4E262C-EA71-4206-9DFE-E7021A2E6035

P577

Q28202603-F8988777-7E0C-47A8-8340-6EA79E295688

P5875

Q28202603-C6B8325D-1EE0-4E30-859A-E06012C3D7EB

P698

Q28202603-61D7198A-E2EE-4BAF-9A79-3E3858140B0F

P3181

P356

S0006-291X(03)01451-7

P1433

Biochemical and Biophysical Research Communications

P1476

Structure-based design of aliskiren, a novel orally effective renin inhibitor

@en

P2093

Chris Jensen

http://www.w3.org/2001/XMLSchema#string

Christian R Schnell

http://www.w3.org/2001/XMLSchema#string

Eoin O'Brien

http://www.w3.org/2001/XMLSchema#string

Frederic Cumin

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Baum

http://www.w3.org/2001/XMLSchema#string

Heinrich Rüger

http://www.w3.org/2001/XMLSchema#string

Jeanette M Wood

http://www.w3.org/2001/XMLSchema#string

Joseph Rahuel

http://www.w3.org/2001/XMLSchema#string

Jürgen Maibaum

http://www.w3.org/2001/XMLSchema#string

Markus G Grütter

http://www.w3.org/2001/XMLSchema#string

P304

698-705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4688696

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0006-291X(03)01451-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

308

http://www.w3.org/2001/XMLSchema#string

P50

Alice V. Stanton

P577

2003-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6239387

http://www.w3.org/2001/XMLSchema#string

P698

12927775

http://www.w3.org/2001/XMLSchema#string